Posted by Michael Wonder on 07 Aug 2023
Qiagen receives FDA approval for companion diagnostic to Blueprint Medicines’ Ayvakit (avapritinib) in gastro-intestinal stromal tumours
7 August 2023 - QIAGEN’s therascreen PDGFRA RGQ PCR kit approved in US to aid in identifying patients with unresectable or metastatic gastro-intestinal stromal tumours positive for the PDGFRA D842V mutation who may be eligible for treatment with Ayvakit (avapritinib).
Qiagen today announced the US FDA approval of its therascreen PDGFRA RGQ PCR kit (therascreen PDGFRA kit).
